RT @Daver_Leukemia: Thank you!! Outstanding work by Dr Alotaibi and Dr Yilmaz shows that type I vs II FLT3i have different mutational resis…
RT @_TanyaBondar_: Dr. Ahmed Alotaibi and @Daver_Leukemia now presenting data on distinct genetic patterns of resistance to type 1 vs 2 Flt…
Proud to present our work at #ASH2020| and have it published @BCD_AACR today. https://t.co/M58jTija80 Thank you very much @Daver_Leukemia @musayilmaz54 @sanamloghavi @doctorpemm @TapKadia @DrHKantarjian @LeukemiaMDA
RT @doctorpemm: #ASH20 | @AAlotaibi_MD & @Daver_Leukemia This report is now in @BCD_AACR Patterns of Resistance Differ in Patients with Acu…
RT @doctorpemm: #ASH20 | @AAlotaibi_MD & @Daver_Leukemia This report is now in @BCD_AACR Patterns of Resistance Differ in Patients with Acu…
RT @doctorpemm: #ASH20 | @AAlotaibi_MD & @Daver_Leukemia This report is now in @BCD_AACR Patterns of Resistance Differ in Patients with Acu…
@RobertaDemiche3
Congrats to @AAlotaibi_MD @Daver_Leukemia and the rest of our team! #leusm #hemepath #hemepathMDA
RT @_TanyaBondar_: Dr. Ahmed Alotaibi and @Daver_Leukemia now presenting data on distinct genetic patterns of resistance to type 1 vs 2 Flt…
RT @Daver_Leukemia: Thank you!! Outstanding work by Dr Alotaibi and Dr Yilmaz shows that type I vs II FLT3i have different mutational resis…
Thank you!! Outstanding work by Dr Alotaibi and Dr Yilmaz shows that type I vs II FLT3i have different mutational resistance/escape and are not competitors but complimentary/sequential strategies @musayilmaz54 @AAlotaibi_MD @doctorpemm @TapKadia @Leukemia
#ASH20 | @AAlotaibi_MD & @Daver_Leukemia This report is now in @BCD_AACR Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated w/Type I versus Type II FLT3-inhibitors https://t.co/EVlp5EKevG #leusm @kanagalshamanna @doctorpemm @
RT @BCD_AACR: #OnlineFirst and at #ASH20: Resistance Patterns Differ in AML Patients Treated with Type I versus Type II FLT3-inhibitors. h…
RT @_TanyaBondar_: Dr. Ahmed Alotaibi and @Daver_Leukemia now presenting data on distinct genetic patterns of resistance to type 1 vs 2 Flt…
RT @SmithLabSF: 8) Caveats: heterogeneous cohort, included pts treated with combos. Great work though @Daver_Leukemia and team #ASHKudos.…
8) Caveats: heterogeneous cohort, included pts treated with combos. Great work though @Daver_Leukemia and team #ASHKudos. Read more about it here: https://t.co/eRfPgs20p5
RT @LugoMd: Happy to share the recently published paper @BCD_AACR presented at #ASH20 @AAlotaibi_MD @Daver_Leukemia where they describe mut…
RT @LugoMd: Happy to share the recently published paper @BCD_AACR presented at #ASH20 @AAlotaibi_MD @Daver_Leukemia where they describe mut…
Happy to share the recently published paper @BCD_AACR presented at #ASH20 @AAlotaibi_MD @Daver_Leukemia where they describe mutations that emerge at relapse after FLT3-i Tx https://t.co/s4PGtxzxy7, and check our commentary @aditishasMD @Amitvermamds https:
Dr. Ahmed Alotaibi and @Daver_Leukemia now presenting data on distinct genetic patterns of resistance to type 1 vs 2 Flt3 inhibitors in #AML, in primary and relapse settings. Read this concurrent publication in @BCD_AACR: https://t.co/uC2SMcqIgG. Artwork s
#OnlineFirst and at #ASH20: Resistance Patterns Differ in AML Patients Treated with Type I versus Type II FLT3-inhibitors. https://t.co/dJDpISgrrW Related commentary: Understanding FLT3 Inhibitor Resistance to Rationalize Combinatorial AML Therapies. ht